Eurosurv. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021

[tetano]

• Iván Martínez-Baz[SUP]1,2,3[/SUP] , Camino Trobajo-Sanmartín[SUP]3,4[/SUP] , Ana Miqueleiz[SUP]3,4[/SUP] , Marcela Guevara[SUP]1,2,3[/SUP] , Miguel Fernández-Huerta[SUP]3,4[/SUP] , Cristina Burgui[SUP]1,2,3[/SUP] , Itziar Casado[SUP]1,2,3[/SUP] , María Eugenia Portillo[SUP]3,4[/SUP] , Ana Navascués[SUP]3,4[/SUP] , Carmen Ezpeleta[SUP]3,4[/SUP] , Jesús Castilla[SUP]1,2,3[/SUP] , the Working Group for the Study of COVID-19 in Navarre[SUP]5[/SUP]

COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (−26 to 45) for Janssen to 68% (48 to 80) for Spikevax; and against hospitalisation from 74% (43 to 88) for Janssen to > 90% for other products. Two doses of vaccine were highly effective against hospitalisation, but suboptimal for infection control.

full article
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.39.2100894#html_fulltext